» Articles » PMID: 29288735

Myelin Changes at the Early Stage of 5XFAD Mice

Overview
Journal Brain Res Bull
Specialty Neurology
Date 2017 Dec 31
PMID 29288735
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have demonstrated myelin deficits in Alzheimer's disease (AD). However, it is still unclear whether myelin deficits occur at early stage of AD. Our study aimed to investigate myelin deficits in 5XFAD mice dynamically in different cognition-associated brain regions at early stage of AD. Transmission electron microscopy (TEM) was applied to detect myelin changes in late-myelinating regions such as prelimbic area (PrL), retrosplenial granular cortex (Rsg), field CA1 of hippocampus (CA1) and entorhinal cortex (ERC) respectively at different stages (1, 2, 3 and 5 months of age) in 5XFAD mouse model. In addition, we assessed spatial learning and memory with Morris water maze (MWM) in 5XFAD mice. Myelin deficits in 5XFAD mice started from 1 month of age and this deterioration continued during ageing, whereas the same myelin abnormality could only be observed in 5-month-old wild-type mice. Additionally, the g-ratio (an index associated with myelin thickness) was increased in 1-month-old 5XFAD mice in the regions including PrL, CA1 and ERC, compared to wild-type mice. As animals aged, the increased g-ratio in 5XFAD appeared in more regions of the brain. Moreover, 5XFAD mice showed spatial memory deficits from 1 month of age and spatial learning deficits from 2 months of age. In conclusion, myelin deficits occurred at an early stage and progressed with ageing in 5XFAD mouse model. Notably, a sequential myelin change was detected in cognition-associated brain regions. Combined with cognitive examinations, this study suggests that myelin changes might contribute to cognitive dysfunction.

Citing Articles

ApoE2 affects insulin signaling in the hippocampus and spatial cognition of aged mice in a sex-dependent manner.

Wang Y, Liu H, Ye Y, Fang W, Lin A, Dai X Cell Commun Signal. 2025; 23(1):112.

PMID: 40011916 PMC: 11866816. DOI: 10.1186/s12964-025-02093-3.


Evolution of Alzheimer's Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy.

Ortiz-Islas E, Montes P, Rodriguez-Perez C, Ruiz-Sanchez E, Sanchez-Barbosa T, Pichardo-Rojas D Pharmaceutics. 2025; 17(1).

PMID: 39861773 PMC: 11768419. DOI: 10.3390/pharmaceutics17010128.


Anthranilic Acid-G-Protein Coupled Receptor109A-Cytosolic Phospholipase A2-Myelin-Cognition Cascade: A New Target for the Treatment/Prevention of Cognitive Impairment in Schizophrenia, Dementia, and Aging.

Oxenkrug G Int J Mol Sci. 2025; 25(24.

PMID: 39769034 PMC: 11675959. DOI: 10.3390/ijms252413269.


Mechanism and Clinical Application Prospects of Mitochondrial DNA Single Nucleotide Polymorphism in Neurodegenerative Diseases.

Xu M, Li T, Liu X, Islam B, Xiang Y, Zou X Neurochem Res. 2024; 50(1):61.

PMID: 39673588 DOI: 10.1007/s11064-024-04311-9.


Proteomic analysis and experimental validation reveal the blood-brain barrier protective of Huanshaodan in the treatment of SAMP8 mouse model of Alzheimer's disease.

Su Y, Liu N, Wang P, Shang C, Sun R, Ma J Chin Med. 2024; 19(1):137.

PMID: 39369234 PMC: 11456246. DOI: 10.1186/s13020-024-01016-7.